about
Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophreniaProlactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics.Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.NMDA receptor genotypes associated with the vulnerability to develop dyskinesiaCatalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia.No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia.Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine.Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia.CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy.Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility.Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia.[Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease][Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics][An effect of quetiapine on the immune system of patients with schizophrenia]Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patientsCortisol and DHEAS Related to Metabolic Syndrome in Patients with SchizophreniaAssociation of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
P50
Q35626932-63DBDF98-9F6E-4DE1-B2E4-A4A5948EFF35Q35779904-D43F9FA1-E3AE-4880-B6A0-4B551D55C7E0Q40518115-ADA963FA-4794-4E00-A7EC-8B419AA5BCA8Q40571585-A39F00D4-8269-43B7-A2A3-A19EAA67B418Q42072420-E51C28DC-AB5C-4140-8C0F-5DB788BA717DQ42363520-08210D8E-966F-4790-A585-C7EC42A01D98Q45232895-47C162C3-86F2-4834-A1EE-600D4CAE070CQ46014091-A476489D-3C12-4AB6-B882-DB4B1968F4A8Q47589447-10156AEA-6D2D-464D-875C-6CB670960156Q47964432-B831D623-CC7C-4957-9149-C69783E36F94Q50535669-11821571-9327-42B3-8828-9DC900B7BEF5Q50552178-92F04205-D660-4DD8-A603-187008D15515Q50600844-73FA4B57-32C1-48CC-B463-80E4A623DE7FQ50667444-77BFE1AF-886A-4337-952B-A32AF409FD5FQ62926198-E78CDDE4-5102-4E1B-8D0B-960A3F67706EQ85487704-C5B862F8-B4F1-4899-B7F0-0EC1B3F6C5BEQ88080236-F2A93CC7-292D-4AA6-846F-FEB5A473DF18Q89121714-4946DCCB-9127-4BD4-BF6C-283D93F941F6Q94525694-456819C4-A6DA-4F0E-A62F-031756792757Q94526057-E081874E-551C-4B45-9046-F445B46D3009
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
A Semke
@ast
A Semke
@es
A Semke
@nl
Arkadi Walentinowitsch Semke
@de
Arkady V. Semke
@en
Аркадий Валентинович Семке
@ru
type
label
A Semke
@ast
A Semke
@es
A Semke
@nl
Arkadi Walentinowitsch Semke
@de
Arkady V. Semke
@en
Аркадий Валентинович Семке
@ru
altLabel
Arkadi Semke
@de
Arkady Semke
@en
Arkady Valentinovich Semke
@en
prefLabel
A Semke
@ast
A Semke
@es
A Semke
@nl
Arkadi Walentinowitsch Semke
@de
Arkady V. Semke
@en
Аркадий Валентинович Семке
@ru
P106
P1153
56004076800
P21
P31
P496
0000-0002-8698-0251